OncoShell: A rapid functional test of breast cancer drug sensitivity
Unmet Medical Need: More than 300,000 breast cancer patients are diagnosed annually in the United States, and a significant subset experience cancer progression and/or recurrence. Such patients account for the ~40,000 annual deaths from the disease and impose substantial financial burden on the healthcare system.
Envisioned Healthcare Product: OncoShell is a functional test that evaluates patient-specific drug response rapidly at low cost to guide chemotherapeutic treatment to reduce the number of patients with progression. Additional target markets include patients with other carcinomas.
Funding Cycle: 2017-2018